See how peptides differ.
Compare up to three compounds. See their targets, study limits, and original sources side by side.
Compare study context. Different populations, models and outcomes can make results unsuitable for direct comparison. These selected records are not a head-to-head trial or a ranking. Source extraction is assisted by AI; independent study-quality review is pending.
“Not extracted” describes a gap in this table, not an absence of research.
Scroll sideways to see all the compounds.
| Research detail | MetabolicSemaglutide GLP-1 analog Study extraction pending. | MetabolicTirzepatide GIP GLP-1 co-agonist Study extraction pending. | MetabolicRetatrutide LY3437943 |
|---|---|---|---|
| Molecular identity |
|
|
|
| Research target | GLP-1 receptor | GIP and GLP-1 receptors | GIP, GLP-1 and glucagon receptors |
| Research available | Evidence availableEvidence for a defined medicine | Evidence availableEvidence for a defined medicine | Evidence availableHuman studies exist |
| Source mapping | 1 of 3 summary statements mapped. Independent expert review pending. | 0 of 3 summary statements mapped. Independent expert review pending. | 1 of 3 summary statements mapped. Independent expert review pending. |
| Material in this study | Not extracted for this exact entry | Not extracted for this exact entry | Retatrutide (LY3437943), study formulation |
| Study design | Not extracted for this exact entry | Not extracted for this exact entry | Phase 2 randomized, double-blind, placebo-controlled trial |
| Population or model | Not extracted for this exact entry | Not extracted for this exact entry | Adults with obesity, or overweight with a weight-related condition |
| Sample size | Not extracted for this exact entry | Not extracted for this exact entry | 338 |
| Comparator | Not extracted for this exact entry | Not extracted for this exact entry | Placebo |
| Duration | Not extracted for this exact entry | Not extracted for this exact entry | 48 weeks; primary body-weight endpoint at 24 weeks |
| Outcomes measured | Not extracted for this exact entry | Not extracted for this exact entry | Percentage change in body weight Safety assessments |
| Study limitations | Not extracted for this exact entry | Not extracted for this exact entry | This trial does not establish equivalence for another formulation or a research vial. |
| Research context | Use the current label for the exact product and population. A trial of a finished medicine does not establish equivalence for a research vial or semaglutide salt. | Distinguish diabetes, weight-management and obstructive-sleep-apnea evidence. Receptor activity alone does not predict comparative clinical outcomes. | Interpret weight changes with trial duration, escalation, discontinuations and comparator in view. Consult the trial register for subsequent development. |
| Identity checks | Confirm the modified sequence, acylation, counterion and formulation. Semaglutide base and salt forms must not be treated as interchangeable. | Check the full modified structure and lipid side chain. A backbone length or purity percentage does not establish pharmaceutical equivalence. | Distinguish the studied molecule from other triple agonists and from commercially described salts or research preparations. |
| Study source | Not extracted for this exact entry | Not extracted for this exact entry | Retatrutide phase 2 obesity trial — publisher full text PDF page 1, Abstract: Methods and Results Checked |
| Full record and references | Open Semaglutide | Open Tirzepatide | Open Retatrutide |
Check what each study tested. Results for one molecular form or study setting may not apply to another. Study registration, measured outcomes and regulatory approval are separate questions.
Keep this comparison close.
Get these compounds, their evidence notes, original sources, and a comparison checklist in one pack. Your compounds and selected studies carry over.
Get my research pack